Put companies on watchlist
PharmaSGP Holding SE
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PharmaSGP Holding SE · ISIN: DE000A2P4LJ5 · EQS - adhoc news (55 News)
Country: Germany · Primary market: Germany · EQS NID: 1208235
15 June 2021 06:02PM

PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt  and Kamol) from GSK


DGAP-Ad-hoc: PharmaSGP Holding SE / Key word(s): Mergers & Acquisitions
PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt  and Kamol) from GSK

15-Jun-2021 / 18:02 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

At the same time publication pursuant to § 111c of the German Stock Corporation Act (Aktiengesetz)
 

PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt and Kamol) from GSK

Gräfelfing, June 15, 2021 - PharmaSGP GmbH, a subsidiary of PharmaSGP Holding SE, has signed today an agreement to acquire a product portfolio with four established OTC brands in eight countries with the GlaxoSmithKline Group. The portfolio focuses on the phytopharmaceuticals of the brand Baldriparan(R), the leading OTC brand for natural valerian sleep aids in pharmacies in Germany.1 In addition, PharmaSGP GmbH acquires Formigran(R), Spalt(R) and Kamol(R), three further well-known OTC brands in the strategically important category "pain therapy". In total, this brand portfolio generated revenues of more than EUR 15 million in eight countries in 2020. In addition to the home market of Germany, also the markets of Austria, Switzerland, France, Hungary, Poland, the Czech Republic and Slovakia contributed to this.

The products are to be integrated into the PharmaSGP Group's pan-European platform, thereby leveraging potential for value enhancement. With the acquisition, the Management Board is consistently pursuing the growth strategy and expanding the portfolio with established brands, increasing the number of indications and further expanding the internationalization of the Group.

The agreed purchase price is around EUR 80 million. In addition, the corresponding product inventories will be taken over against payment. The Management Board of PharmaSGP Holding SE expects the transaction to be completed by the end of August 2021.

The acquisition is financed through a shareholder loan granted to PharmaSGP Holding SE by FUTRUE GmbH on the basis of a loan agreement concluded today. FUTRUE GmbH has a majority shareholding in PharmaSGP Holding SE and is in turn solely owned by the Chairman of the Supervisory Board of PharmaSGP Holding SE. Therefore, the financing is a transaction of the Company with a related party subject to disclosure pursuant to Section 111c of the German Stock Corporation Act (Aktiengesetz). The shareholder loan granted to PharmaSGP Holding SE is unsecured and has a volume of EUR 85 million. It has a minimum term until December 31, 2021 and is then automatically extended by further three-month periods until December 31, 2022 at the latest, unless it is terminated by the lender prior to respective extension. The loan interest rate will be determined based on a benchmark analysis for the applicable market interest rate, which has yet to be carried out. For undrawn volumes, a commitment fee of 35% of the loan interest rate will be payable for the period from August 25, 2021.

The Company intends to refinance the shareholder loan at maturity through bank financing.

1 in terms of revenue in 2020


15-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 21
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com
Internet: https://pharmasgp.com
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich
EQS News ID: 1208235

 
End of Announcement DGAP News Service

1208235  15-Jun-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1208235&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PharmaSGP Holding SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.